目的 探讨润肺止嗽丸联合布地奈德福莫特罗治疗慢性阻塞性肺疾病缓解期的临床疗效。方法 选取2020年6月—2022年12月定州市人民医院收治的128例慢性阻塞性肺疾病缓解期患者，按照随机数字表法将所有患者分为对照组和治疗组，每组各64例。对照组患者经口吸入布地奈德福莫特罗粉吸入剂，1～2吸/次，2次/d。治疗组在对照组的基础上口服润肺止嗽丸，2丸/次，2次/d。两组均连续治疗8周。治疗后，比较两组症状缓解时间、肺功能指标和血清炎性因子水平。结果 治疗后，治疗组总有效率是98.44%，显著高于对照组的84.38%（P＜0.05）。治疗后，治疗组咳嗽、咳痰、气短、疲乏缓解时间均显著短于对照组（P＜0.05）。治疗后，两组第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1占预测值百分比（FEV1%）均较治疗前显著升高（P＜0.05）；治疗后，治疗组FEV1、FVC、FEV1%均高于对照组（P＜0.05）。治疗后，两组患者白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、血清内皮素-1（ET-1）水平均较治疗前显著降低，而降钙素基因相关肽（CGRP）水平均显著提高（P＜0.05）；治疗后，治疗组血清炎性因子水平改善优于对照组（P＜0.05）。结论 润肺止嗽丸联合布地奈德福莫特罗粉治疗慢性阻塞性肺疾病缓解期效果确切，可有效缓解患者临床症状，改善肺功能指标，调节血清炎性细胞因子水平，值得临床借鉴推广。

Objective To investigate the clinical effect of Runfei Zhisou Pills combined with budesonide and formoterol fumarate powder in chronic obstructive pulmonary disease in remission stage. Methods A total of 128 patients with chronic obstructive pulmonary disease in remission period admitted to Dingzhou People's Hospital from June 2020 to December 2022 were selected and divided into control group and treatment group according to random number table method, with 64 patients in each group. Patients in the control group inhaled Budesonide and Formoterol Fumarate Powder for inhalation orally, 1-2 puffs/time, twice daily. Patients in the treatment group were po administered with Runfei Zhisou Pills on the basis of the control group, 2 pills/time, twice daily. Both groups were treated continuously for 8 weeks. After treatment, symptom remission time, pulmonary function indexes and serum inflammatory factors levels were compared between two groups. Results After treatment, the total effective rate of the treatment group was 98.44%, which was significantly higher than that of the control group (84.38%, P < 0.05). After treatment, the relief time of cough, expectoration, shortness of breath and fatigue in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and the percentage of FEV1 to predicted value (FEV1%) of both groups were significantly increased compared with those before treatment (P < 0.05). After treatment, FEV1, FVC and FEV1% in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and serum endothelin-1 (ET-1) in two groups were significantly decreased compared with before treatment, while the levels of CGRP were significantly increased (P < 0.05). After treatment, the level of serum inflammatory factors in treatment group was better than that in control group (P < 0.05). Conclusion Runfei Zhisou Pills combined with budesonide and formoterol fumarate has a definite effect in chronic obstructive pulmonary disease in remission stage, and can improve lung function indicators, regulate the level of serum inflammatory cytokines, which is worthy of clinical reference and promotion.

R974

河北省医学科学研究课题（20191747）